Dr. Rebecca Feldman on Caveolin-1 and its Potential in Breast Cancer Treatment
Rebecca Feldman, PhD, molecular science liaison/research scientist, Caris Life Sciences, discusses caveolin-1, which has the potential to play a major role in the treatment of breast cancer.
Rebecca Feldman, PhD, molecular science liaison/research scientist, Caris Life Sciences, discusses caveolin-1, which has the potential to play a major role in the treatment of breast cancer.
Feldman says that by targeting caveolin-1, medical professionals could potentially restrict the growth of breast cancer in a patient. She adds that by targeting caveolin-1 and restricting breast cancer growth, new treatments that target EGFR and PDGFRA could also become a possibility. This is due to caveolin-1’s role of signaling processes on the molecular level.
T-DXd Maintains QOL, Delays Pain Deterioration in HR+/HER2-Low/Ultralow MBC
September 15th 2024Patient-reported outcomes from DESTINY-Breast06 show trastuzumab deruxtecan improved time to deterioration for pain and other subscores, with no decline in overall QOL in either arm in the HER2 low/ultralow breast cancer setting.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Therapy Changes for Metastases and Toxicity Discussed in Breast Cancer
September 5th 2024During a Case-Based Roundtable® event, Ian Krop, MD, PhD, and event participants discussed how different types of metastases and treatment toxicity would affect therapy given to patients with triple-positive breast cancer in the second article of a 2-part series.
Read More
